InDex Pharmaceuticals
Flerie is a diversified investment company focused on advancing innovative biotech and pharmaceutical companies globally. They support a broad portfolio of companies at various stages of development, from early-stage research to late-stage clinical trials and commercialization. Their mission is to foster innovation in life sciences, leveraging strategic investments, partnerships, and M&A activities to accelerate the development of transformative therapies and technologies.
Industries
Nr. of Employees
small (1-50)
InDex Pharmaceuticals
Skeppsbron 16, SE-111 30 Stockholm, Sweden
Patents
Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells
US-10046006-B2
View DetailsMethod for identifying biologically active oligonucleotides capable of modulating the immune system
US-9157919-B2
View Details
Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells
US-10046006-B2
View DetailsMethod for identifying biologically active oligonucleotides capable of modulating the immune system
US-9157919-B2
View DetailsServices
Providing long-term, balance-sheet-funded equity investments and active operational support to build and scale life-science companies across preclinical to commercial stages.
Enabling shared use of production, clinical study resources and expert consultants across portfolio companies and facilitating peer-to-peer exchanges between company leadership and KOLs.
Coordinating capital raises, investor communications, financial reporting and public disclosures including interim reports, NAV updates and webcasts.
Supporting companies with market entry, distribution scaling and business development for organisations in commercial growth stage.
Connecting portfolio companies with contract development and manufacturing organisations, and supporting selection and negotiation of manufacturing alliances for biologics and advanced therapies.
Providing long-term, balance-sheet-funded equity investments and active operational support to build and scale life-science companies across preclinical to commercial stages.
Enabling shared use of production, clinical study resources and expert consultants across portfolio companies and facilitating peer-to-peer exchanges between company leadership and KOLs.
Coordinating capital raises, investor communications, financial reporting and public disclosures including interim reports, NAV updates and webcasts.
Supporting companies with market entry, distribution scaling and business development for organisations in commercial growth stage.
Connecting portfolio companies with contract development and manufacturing organisations, and supporting selection and negotiation of manufacturing alliances for biologics and advanced therapies.
Expertise Areas
- Life-science company building and active ownership
- Investment structuring and capital raises
- Portfolio valuation and NAV reporting
- Clinical development strategy and oversight
Key Technologies
- Cell therapy (allogeneic)
- Dendritic cell-based immunotherapies
- Gene therapy and viral vector platforms
- mRNA and RNA delivery platforms
News & Updates
KAHR Bio announced positive Phase II results at the 2025 ASCO Annual Meeting, demonstrating anti-tumour activity and extended survival in patients with third-line microsatellite stable metastatic colorectal cancer.
Nanologica secured an order for its silica-based purification media NLAB Saga® from a new customer in the U.S., marking its entry into the North American market.
KAHR Bio announced positive Phase II results at the 2025 ASCO Annual Meeting, demonstrating anti-tumour activity and extended survival in patients with third-line microsatellite stable metastatic colorectal cancer.
Nanologica secured an order for its silica-based purification media NLAB Saga® from a new customer in the U.S., marking its entry into the North American market.